APC-Targeted DNA Vaccination Against Reticulocyte-Binding Protein Homolog 5 Induces
Animals
Antibodies, Neutralizing
/ immunology
Antibodies, Protozoan
/ immunology
Antibody Specificity
/ immunology
Antigen-Presenting Cells
/ immunology
Antigens, Protozoan
/ immunology
Carrier Proteins
/ immunology
Disease Models, Animal
Epitopes
/ immunology
Female
Gene Order
Genetic Vectors
/ genetics
Immunization
Malaria Vaccines
/ immunology
Malaria, Falciparum
/ immunology
Mice
Plasmodium falciparum
/ immunology
T-Lymphocytes
/ immunology
Vaccines, DNA
/ immunology
APC-targeting
DNA vaccines
GIA
PfRH5
T cell responses
antibody responses
malaria
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
06
2021
accepted:
30
09
2021
entrez:
4
11
2021
pubmed:
5
11
2021
medline:
22
12
2021
Statut:
epublish
Résumé
Targeted delivery of antigen to antigen presenting cells (APCs) is an efficient way to induce robust antigen-specific immune responses. Here, we present a novel DNA vaccine that targets the
Identifiants
pubmed: 34733274
doi: 10.3389/fimmu.2021.720550
pmc: PMC8558525
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Protozoan
0
Antigens, Protozoan
0
Carrier Proteins
0
Epitopes
0
Malaria Vaccines
0
RH5 protein, Plasmodium falciparum
0
Vaccines, DNA
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
720550Subventions
Organisme : Wellcome Trust
ID : 106917/Z/15/Z
Pays : United Kingdom
Informations de copyright
Copyright © 2021 Bjerkan, Visweswaran, Gudjonsson, Labbé, Quinkert, Pattinson, Spång, Draper, Bogen and Braathen.
Déclaration de conflit d'intérêts
SD is a named inventor on patent applications relating to RH5 and/or other malaria vaccines and immunization regimens. BB and RB are inventors on patent applications filed on the vaccine molecules by the Technology Transfer Offices of the University of Oslo and Oslo University Hospital, according to institutional rules. BB is head of the scientific panel of Vaccibody AS. The other authors have no financial conflicts of interest. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Med. 2008 Aug;14(8):819-21
pubmed: 18660818
J Immunol. 2017 Apr 1;198(7):2785-2795
pubmed: 28228559
Mol Ther. 2014 Dec;22(12):2142-2154
pubmed: 25156127
J Immunol. 2013 Sep 15;191(6):3221-31
pubmed: 23956431
Blood. 2007 Sep 15;110(6):1797-805
pubmed: 17540847
Sci Transl Med. 2009 Oct 14;1(2):2ra5
pubmed: 20165550
J Immunol. 2016 Nov 1;197(9):3575-3585
pubmed: 27671110
Trends Parasitol. 2020 Jun;36(6):545-559
pubmed: 32359873
PLoS One. 2011;6(5):e20547
pubmed: 21655233
Nature. 2014 Nov 20;515(7527):427-30
pubmed: 25132548
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20735-40
pubmed: 24297912
Parasite Immunol. 1987 Jan;9(1):1-9
pubmed: 2436129
Front Immunol. 2015 Jul 20;6:367
pubmed: 26257735
J Infect Dis. 2016 Jun 1;213(11):1743-51
pubmed: 26908756
Int J Parasitol. 2009 Feb;39(3):371-80
pubmed: 19000690
Infect Immun. 2006 Aug;74(8):4573-80
pubmed: 16861644
Science. 1998 Oct 16;282(5388):476-80
pubmed: 9774275
J Immunol Methods. 1997 May 12;204(1):77-87
pubmed: 9202712
J Exp Med. 1998 Apr 20;187(8):1193-204
pubmed: 9547331
Vaccine. 2019 Feb 4;37(6):817-826
pubmed: 30638800
PLoS One. 2014 Aug 14;9(8):e104814
pubmed: 25122197
J Virol. 2014 Jan;88(1):314-24
pubmed: 24155379
NPJ Vaccines. 2019 Feb 11;4:9
pubmed: 30775000
Appl Microbiol Biotechnol. 2011 Aug;91(3):731-40
pubmed: 21556920
Nat Commun. 2019 Apr 26;10(1):1953
pubmed: 31028254
Cell. 2019 Jun 27;178(1):216-228.e21
pubmed: 31204103
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):998-1002
pubmed: 28096331
Cell Host Microbe. 2015 Jan 14;17(1):130-9
pubmed: 25590760
Nature. 2011 Nov 09;480(7378):534-7
pubmed: 22080952
Front Immunol. 2015 Jul 08;6:348
pubmed: 26217340
Trends Parasitol. 2015 Mar;31(3):87-8
pubmed: 25704640
Nature. 2012 Jul 19;487(7407):375-9
pubmed: 22722859
Clin Vaccine Immunol. 2009 Jul;16(7):963-8
pubmed: 19439523
Immunohorizons. 2018 Jan 18;2(1):38-53
pubmed: 31022690
Lancet. 2013 Nov 23;382(9906):1700-1
pubmed: 24239252
Expert Rev Vaccines. 2013 Apr;12(4):365-78
pubmed: 23560918
J Immunol. 2014 Jan 1;192(1):245-58
pubmed: 24293631
Mol Ther. 2006 Apr;13(4):776-85
pubmed: 16414309
NPJ Vaccines. 2018 Aug 17;3:32
pubmed: 30131879
Annu Rev Immunol. 1989;7:145-73
pubmed: 2523712
Cell Host Microbe. 2018 Jul 11;24(1):43-56
pubmed: 30001524
J Biotechnol. 2012 Dec 31;162(2-3):171-82
pubmed: 22981627
JCI Insight. 2017 Nov 2;2(21):
pubmed: 29093263
Front Immunol. 2019 Jul 04;10:1529
pubmed: 31333661
Immunol Rev. 2011 Jan;239(1):62-84
pubmed: 21198665
Nat Commun. 2011 Dec 20;2:601
pubmed: 22186897
J Virol. 2017 Nov 14;91(23):
pubmed: 28931687